Pharma DECODED
Previous edition: 09 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Sobi's Aspaveli obtains indication extension approval in Europe
The approval for Aspaveli's extended indication is based on data from the APL2-308 (PRINCE) study.
Sobi has received approval for an indication extension from the European Commission for Aspaveli to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
Uncontrolled complement activation in PNH, a chronic and life-threatening blood disorder, leads to the destruction of red blood cells that carry oxygen.
Aspaveli is approved in Europe to treat adult PNH patients who are anaemic following treatment with a C5 inhibitor for at least three months.
It is now the first C3 inhibitor approved for first-line PNH treatment in Europe, potentially improving patient outcomes by addressing haemoglobin levels and other clinical markers.
The approval for Aspaveli's extended indication is based on data from the APL2-308 (PRINCE) study, an open-label, randomised, comparator-controlled trial.
The study included patients who had not received any complement inhibitor treatment within three months before enrolment and exhibited haemoglobin levels below the normal lower limit and lactate dehydrogenase levels at least 1.5 times above the normal upper limit.
Over 26 weeks, the efficacy and safety of Aspaveli were assessed against standard care, which includes treatments such as transfusions and corticosteroids but excludes complement inhibitors.
Sobi chief medical officer and research and development and medical affairs head Lydia Abad-Franch stated: “Today’s approval underscores the robust clinical data supporting Aspaveli 's efficacy and safety profile, offering healthcare professionals and patients an expanded toolkit for effectively managing PNH.
“European patients will now be able to initiate treatment with Aspaveli at diagnosis or switch from their current C5 inhibitor treatment if they present indicators of haemolytic anaemia.”
Aspaveli, known as Empaveli in the US and commercialised by Apellis, is also approved there for the treatment of adults with PNH.
It is under investigation for the potential treatment of other rare diseases across the haematology and nephrology sectors.
Latest news
ESCMID 2024: Emerging bacterial infections in neonates and children
Coinfections can complicate disease management and hence continued surveillance and targeted intervention strategies are needed.
FDA fast track status granted to iECURE neonatal OTC deficiency treatment
ECUR-506 is being evaluated in the first-in-human Phase I/II OTC-HOPE study.
Biotechs must prioritise ethics to deter GenAI “bad actors”
At the London Biotechnology Show, Microsoft’s senior director of life sciences discussed the ethical use of GenAI.
Zenas raises $200m to advance autoimmune antibody therapy
Zenas signed a licensing deal for Asia-Pacific territories for the bispecific antibody therapy, obexelimab, with Bristol Myers Squibb in September 2023.
Regenex Bio eyes FDA meeting to confirm pivotal DMD trial
Regenex Bio will sit down with the FDA in Q3 2024 to finalise the Phase III trial design.
Acepodia reports preliminary results from ACE1831 Phase I trial
The preliminary data indicates potential benefits for non-Hodgkin's lymphoma patients.
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
TEV-‘749 has met primary endpoint in Phase III trial, showing significant symptom reduction in schizophrenia patients.
15th Annual Outsourcing in Clinical Trials East Coast 2024
The upcoming Outsourcing in Clinical Trials Europe 2024 conference will explore advancements in the clinical trial industry.
In our previous edition
Pharma Decoded
AstraZeneca to withdraw Covid-19 vaccine globally
08 May 2024
Pharma Decoded
BioNTech reports net loss of €315.1m in Q1 2024
07 May 2024
Pharma Decoded
Amgen reports a 22% increase in Q1 2024 net revenues
06 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Medical Devices
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer